Nordmann News & Events News Pharmaceutical-grade lactose
29 April 2024

Pharmaceutical-grade lactose

Nordmann partner Armor Pharma, a subsidiary of the Savencia Group, is a French manufacturer of pharmaceutical-grade lactose monohydrate, an excipient designed for use in solid oral dosage forms and dry powder inhalation formulations.

Since 2020, Nordmann has been distributing Armor Pharma’s pharmaceutical-grade lactose products in Germany, including the innovative EXCIPRESS™ SD2L, a spray-dried lactose that is used for a variety of applications in the health sector.

Woman smiling at a pill with a glass of water in her hand

For more information, please contact:

Kathrin Aicher
Kathrin Aicher
Technical Sales & Product Manager | Health Care
Nordmann, Rassmann GmbH

In Armor Pharma, Nordmann has an outstanding partner for several different types of lactose – milled, sieved, agglomerated, and spray-dried – and which comply with the standards established in the European Pharmacopoeia (Ph. Eur.), United States Pharmacopeia (USP-NF) and Japanese Pharmacopoeia (JP). These products are suitable for both solid and inhaled dosage forms.


Built in 2014 and specially designed for producing the company’s pharmaceutical-grade materials, Armor Pharma’s manufacturing facility is situated in Loudéac (France). The plant is certified to EXCIPACT (GMP), ISO 9001, and ISO 22000 standards and undergoes regular audits. 


EXCIPRESS™ SD2L from Armor Pharma is a spray-dried lactose product manufactured under GMP standards and used for the direct compression of tablets. The product also complies with the Ph.Eur, USP-NF, and JP guidelines for lactose monohydrate.


The main advantages of EXCIPRESS™ SD2L include:


  • Excellent compaction properties
  • Very good flowability
Bottle of Excipress by Armor Pharma


Sustainability is now playing an increasingly important role for companies. More and more, businesses are striving to conserve resources and lower their carbon footprints. The Savencia Group likewise demonstrates its commitment through OXYGEN – the name of its corporate social responsibility and sustainable development approach – which emphasizes sustainable agriculture, responsible consumption and minimizing ecological impact. Beyond that, the Savencia Group has joined the Science Based Target initiative (SBTi) to reduce their greenhouse gas emissions in accordance with the Paris Agreement. Specific targets have been set, including a 27.5% reduction in Scope 1 and 2 emissions by 2030 and a 22.5% reduction in Scope 3 emissions per product manufactured. The Savencia Group has already implemented sustainability measures such as high-efficiency hot water systems and are currently in the planning stages for energy audits and testing new sources of energy.

More information on our product portfolio